Bristol Myers (BMY) director Paula A. Price adds 3,996 Deferred Share Units

Rhea-AI Filing Summary

Bristol Myers Squibb director Paula A. Price reported receiving 3,996.367 Deferred Share Units on February 1, 2026 at an indicated value of $55.05 per unit. Following this award, she beneficially owns 25,498.163 Deferred Share Units, held directly.

Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when Price ceases to be a director or at a future date she previously specified, and include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Price Paula A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Share Units	3,996.367	$55.05	$220K

Holdings After Transaction: Deferred Share Units — 25,498.163 shares (Direct)

Footnotes (1)

1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Price Paula A

(Last) (First) (Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON NJ 08543

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Share Units	(1)	02/01/2026		A		3,996.367		(1)	(1)	Common Stock, $0.10 par value	3,996.367	$55.05	25,498.163(2)	D

Explanation of Responses:

1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Remarks:

	/s/ Amy Fallone, attorney-in-fact for Paula A. Price	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bristol Myers Squibb (BMY) disclose for Paula A. Price?

Bristol Myers Squibb disclosed that director Paula A. Price acquired 3,996.367 Deferred Share Units on February 1, 2026. These units are a form of deferred compensation that convert into common stock upon settlement, increasing her total Deferred Share Units to 25,498.163.

How many Deferred Share Units does BMY director Paula A. Price hold after the latest Form 4?

After the reported transaction, Paula A. Price beneficially owns 25,498.163 Deferred Share Units. This total reflects the newly acquired 3,996.367 units plus prior holdings, including deferred compensation and dividends reinvested under Bristol Myers Squibb’s 1987 Deferred Compensation Plan for Non-Employee Directors.

At what value were Paula A. Price’s new Bristol Myers Squibb Deferred Share Units recorded?

The newly acquired 3,996.367 Deferred Share Units for director Paula A. Price were reported at an indicated value of $55.05 per unit. This value is used for reporting purposes in the Form 4 and relates to Bristol Myers Squibb common stock.

When do Bristol Myers Squibb Deferred Share Units for directors like Paula A. Price settle?

Each Deferred Share Unit will convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when the reporting person ceases to be a director or at a future date previously specified by that director in accordance with the plan’s terms.

What plan governs Paula A. Price’s Deferred Share Units at Bristol Myers Squibb (BMY)?

The holdings include deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors. Under this plan, non-employee directors can receive compensation as Deferred Share Units that later convert into Bristol Myers Squibb common stock upon settlement events.

Are Paula A. Price’s Deferred Share Units in BMY held directly or indirectly?

The Form 4 shows direct ownership (D) of 25,498.163 Deferred Share Units by director Paula A. Price. No nature-of-ownership footnote indicates an intermediary entity, so the reported holdings are attributed directly to her under the company’s deferred compensation arrangements.